Andreas Bråve
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andreas Bråve has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Jorma Hinkula
Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
5 shared publications Britta Wahren
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet and Swedish Institute for Infectious Disease Control, Stockholm, Sweden
4 shared publications- Kristian Hallermalm
Division of Vascular Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden
4 shared publications - Andreas Boberg
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden
3 shared publications Erik Rollman
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
3 shared publicationsPontus Blomberg
VECURA, Karolinska University Hospital, Huddinge, Sweden
3 shared publications
Latest Publications
- Open Access
- 1 September 2007
- Published by Elsevier in Molecular Therapy
- Vol. 15 (9) , 1724-1733
A New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice
- 1 September 2007
- Published by Elsevier in Molecular Therapy
- Vol. 15 (9) , 1724-1733
Open AccessA New Multi-clade DNA Prime/Recombinant MVA Boost Vaccine Induces Broad and High Levels of HIV-1-specific CD8+ T-cell and Humoral Responses in Mice
- Open Access
- 10 July 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 14
Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology
The human immunodeficiency virus type 1 (HIV-1) regulatory protein, Nef, is an attractive vaccine target because it is involved in viral pathogenesis, is expressed early in the viral life cycle and harbors many T and B cell epitopes. Several clinical trials include gene-based vaccines encoding this protein. However, Nef has been shown to transform certain cell types in vitro. Based on these findings we performed a long-term toxicity and immunogenicity study of Nef, encoded either by Modified Vaccinia virus Ankara or by plasmid DNA. BALB/c mice were primed twice with either DNA or MVA encoding Nef and received a homologous or heterologous boost ten months later. In the meantime, the Nef-specific immune responses were monitored and at the time of sacrifice an extensive toxicological evaluation was performed, where presence of tumors and other pathological changes were assessed.
- 10 July 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 14
Open AccessImmunization of mice with the nef gene from Human Immunodeficiency Virus type 1: Study of immunological memory and long-term toxicology
The human immunodeficiency virus type 1 (HIV-1) regulatory protein, Nef, is an attractive vaccine target because it is involved in viral pathogenesis, is expressed early in the viral life cycle and harbors many T and B cell epitopes. Several clinical trials include gene-based vaccines encoding this protein. However, Nef has been shown to transform certain cell types in vitro. Based on these findings we performed a long-term toxicity and immunogenicity study of Nef, encoded either by Modified Vaccinia virus Ankara or by plasmid DNA. BALB/c mice were primed twice with either DNA or MVA encoding Nef and received a homologous or heterologous boost ten months later. In the meantime, the Nef-specific immune responses were monitored and at the time of sacrifice an extensive toxicological evaluation was performed, where presence of tumors and other pathological changes were assessed.
- 21 June 2007
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 66 (1) , 43-51
Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer
In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP-produced plasmid DNA vaccine, CEA66, encoding a truncated form of the tumour-associated antigen, CEA. The GMP-produced CEA DNA vaccine was also evaluated for toxicity. Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity. In a heterologous DNA prime/protein boost setting, cellular immune responses were of higher magnitude in animals primed with CEA66 DNA than in animals receiving repeated doses of recombinant CEA protein. These responses were further enhanced if recombinant murine granulocyte-macrophage colony-stimulating factor was given as an adjuvant prior to vaccination. In contrast to repeated administration of recombinant CEA protein as a single modality vaccine, the heterologous CEA66 DNA prime/rCEA boost vaccination strategy resulted in a qualitatively broader immune response, and supports clinical testing of this vaccination regimen in humans.
- 21 June 2007
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 66 (1) , 43-51
Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer
In preparation for a clinical trial in patients diagnosed with colorectal cancer, a vaccination strategy targeting the carcinoembryonic antigen (CEA) was evaluated in mice using a GMP-produced plasmid DNA vaccine, CEA66, encoding a truncated form of the tumour-associated antigen, CEA. The GMP-produced CEA DNA vaccine was also evaluated for toxicity. Repeated intradermal administration of the GMP-produced vaccine using a novel needle-free jet injection device (Biojector) induced robust CD4 and CD8 T-cell responses in mice, and did not result in any vaccine-related toxicity. In a heterologous DNA prime/protein boost setting, cellular immune responses were of higher magnitude in animals primed with CEA66 DNA than in animals receiving repeated doses of recombinant CEA protein. These responses were further enhanced if recombinant murine granulocyte-macrophage colony-stimulating factor was given as an adjuvant prior to vaccination. In contrast to repeated administration of recombinant CEA protein as a single modality vaccine, the heterologous CEA66 DNA prime/rCEA boost vaccination strategy resulted in a qualitatively broader immune response, and supports clinical testing of this vaccination regimen in humans.
- Open Access
- 18 April 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 9
Immunization with HIV protease peptides linked to syngeneic erythrocytes
New potent vaccine adjuvants are desirable for increasing the efficacy of novel vaccine modalities such as DNA and peptides. We therefore tested if syngeneic erythrocytes could serve as delivery vectors for selected HIV peptides and compared the potency of these constructs to immunization with peptides in phosphate buffered saline or in incomplete Freunds adjuvant.
- 18 April 2007
- Published by Springer Nature in Infectious Agents and Cancer
- Vol. 2 (1) , 9
Open AccessImmunization with HIV protease peptides linked to syngeneic erythrocytes
New potent vaccine adjuvants are desirable for increasing the efficacy of novel vaccine modalities such as DNA and peptides. We therefore tested if syngeneic erythrocytes could serve as delivery vectors for selected HIV peptides and compared the potency of these constructs to immunization with peptides in phosphate buffered saline or in incomplete Freunds adjuvant.
- Open Access
- 1 December 2005
- Published by Elsevier in Molecular Therapy
- Vol. 12 (6) , 1197-1205
Multigene/Multisubtype HIV-1 Vaccine Induces Potent Cellular and Humoral Immune Responses by Needle-Free Intradermal Delivery
- 1 December 2005
- Published by Elsevier in Molecular Therapy
- Vol. 12 (6) , 1197-1205
Open AccessMultigene/Multisubtype HIV-1 Vaccine Induces Potent Cellular and Humoral Immune Responses by Needle-Free Intradermal Delivery